Rep. Diana Harshbarger

Build up Illegal Line Defenses with Assets Lawfully Lifted Act of 2023 This bill directs certain amounts from the Department of Justice (DOJ) Assets Forfeiture Fund to the deployment of additional border security measures. Specifically, DOJ must report annually on the amount of total deposits into the fund that are derived from Mexican cartels. The bill makes available 50% of that amount for the construction of additional physical barriers and roads near the border to deter illegal crossings into the United States. Additionally, the bill prohibits the release of seized currency or contraband that likely belongs to or supports a foreign illegal trafficking organization while a civil forfeiture action is pending.

Maddy summaryThis bill helps new car dealers affected by pandemic-era supply chain disruptions by changing tax rules for inventory sales. It allows dealers using LIFO accounting to treat certain sales of unsold vehicles (liquidations) between March 2020 and December 2021 as "qualified" for tax purposes. Dealers can defer recognizing income from these sales and have until 2026 to replace the sold vehicles before potential tax adjustments apply. The provision specifically targets dealers who couldn't replenish inventory during the supply chain crisis.

Tennessee Valley Authority Transparency Act of 2023 This bill revises the duties of the Tennessee Valley Authority (TVA) Board of Directors to include holding public meetings. The board must provide public notice at least six days before such a meeting, unless the meeting is designated as an emergency. The TVA provides low-cost electricity in seven southeastern states. It also provides flood control, navigation, and land management for the Tennessee River system.

Maddy summaryThis symbolic House resolution (HRES 72) recognizes independent workers, contractors, and freelancers for their economic contributions to the U.S. It highlights their role in the growing flexible work economy and acknowledges the benefits of flexible work arrangements, such as freedom in hours and locations. The resolution does not create new laws or alter existing policies - it solely serves as a formal acknowledgment of these workers' significance to the economy. It references their $1.35 trillion economic contribution in 2022 and their growing share of the workforce (39% of U.S. workers).

This resolution recognizes and appreciates the dedication and devotion demonstrated by the men and women of law enforcement. It also condemns calls to defund, disband, dismantle, or abolish the police.

This resolution expresses the sense of the House of Representatives that (1) the President should classify synthetic illicit fentanyl-related substances as weapons of mass destruction; and (2) illicit fentanyl, and illicit fentanyl-related substances, should be permanently placed in schedule I (i.e., as drugs, substances, or chemicals with no currently accepted medical use and a high potential for abuse).

Maddy summaryThis bill would prohibit the FDA from approving new abortion medications or investigational uses of existing ones. It would restrict currently approved abortion drugs to in-person administration only in clinics, hospitals, or medical offices by certified providers who can handle complications like ectopic pregnancy or severe bleeding. The law requires detailed adverse event reporting (excluding patient identifiers) to the FDA by both manufacturers and prescribers, and mandates provider certification covering pregnancy assessment, surgical intervention capabilities, and patient safety documentation. These provisions apply directly to healthcare providers, patients seeking medication abortions, and manufacturers of abortion drugs.

Essential Medicines Strategic Stockpile Act of 2023 This bill requires the Department of Health and Human Services (HHS) to create a pilot program to test the effectiveness of acquiring, maintaining, managing, and distributing a stockpile of generic drugs at risk of shortage. To carry out the pilot program, HHS must enter into contracts for a term of up to three years with drug manufacturers, co-op or chain pharmacy warehouses, or other eligible entities to create a six-month stockpile of up to 50 types of such drugs. The bill establishes various program requirements, including annual evaluations by the Government Accountability Office.

Protecting Life and Taxpayers Act of 2023 This bill requires federally funded entities to certify that they will not, subject to certain exceptions, perform abortions or provide funding to other entities that perform abortions. The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness.

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.